MetLife, Inc.
NYSE:METInsurance - Life
-$0.15 today
- Market cap
- $62.71B
- Beta
- 0.78
- P/E (TTM)
- 15.4
- EPS (TTM)
- $5.55
- Dividend yield
- 2.68%
Volume 4.27M
Average 3.49M
MET Other Investing Activities
Investing cash flows not reported separately.
MetLife, Inc.NYSE: MET
Other Investing Activities · Q2 FY2026 · quarter ended Jun 2026
Other investing activities turns negative
Q2 FY2026 other investing activities was -$782M, compared with $757M a year earlier. Trailing-twelve-month other investing activities was -$348M. Over 3 fiscal years it compounded at -28.9% a year.
Context
- Other investing activities amounted to 2.7% of revenue in FY2025, up 1.1 pp from a year earlier.
- Other investing activities increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other investing activities holds near -$782M or moves back toward the trailing-twelve-month quarterly average of -$87M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Investing Activities history
USD · from the cash flow
- Latest · FY2025
- (2.04B) USD
- Year-over-year change
- -291.7%
| Period | Period end | Other Investing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.04B) | -291.7% |
| FY2024 | 2024-12-31 | 1.07B | +845.5% |
| FY2023 | 2023-12-31 | (143M) | +97.5% |
| FY2022 | 2022-12-31 | (5.7B) | +71.9% |
| FY2021 | 2021-12-31 | (20.29B) | — |
Other Investing Activities vs competitors
How MET compares with its peers on the latest reported figures
- Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -116.0% is the 10th highest of 11, against a peer median of +194.3%.
- Other investing activities amounts to 0.4% of revenue for MET, versus a peer median of 9.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | CA$16.57B CAD | -20.7% | -77.4% | 28.6% | |
| LTM Jun 2026 | $16.39B USD | +625.6% | — | 84.7% | |
| LTM Jun 2026 | $9.98B USD | +527.0% | — | 55.2% | |
| LTM Jun 2026 | $2.1B USD | +516.7% | — | 15.8% | |
| LTM Sep 2026 | $1.63B USD | -159.9% | — | 30.1% | |
| LTM Jun 2026 | $673M USD | -73.1% | — | 1.0% | |
| LTM Jun 2026 | $348M USD | -116.0% | -28.9% | 0.4% | |
| LTM Jun 2026 | $89M USD | +163.1% | — | 2.4% | |
| LTM Jun 2026 | $67.13M USD | +251.3% | — | 1.1% | |
| LTM Jun 2026 | $26.83M USD | +225.5% | — | 0.8% | |
| LTM Jun 2026 | $4M USD | -76.5% | -62.6% | 0.1% | |
| Peer median (excluding MET) | — | +194.3% | -70.0% | 9.1% | |
Competitors are the stored peer set for MET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 6.55B | 5.28B | 1.58B | 4.43B | 3.38B |
| Depreciation & Amortization | 694M | 673M | 718M | 714M | 753M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 2.64B | 1.9B | 2.18B | 1.85B | 6.84B |
| Accounts Receivables | 362M | 299M | 0 | 460M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 2.27B | 1.6B | 2.18B | 1.39B | 6.84B |
| Other Non-Cash Items | 2.94B | 3.52B | 9.78B | 8.13B | 7.14B |
| Operating Cash Flow | 12.83B | 11.37B | 14.26B | 15.12B | 18.11B |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 3.27B | (709M) | (755M) | (358M) | (738M) |
| Purchases of Investments | (109.32B) | (104.64B) | (84.27B) | (82.14B) | (105.7B) |
| Sales of Investments | 110.79B | 108.43B | 76.1B | 69.94B | 92.87B |
| Other Investing Activities | (20.29B) | (5.7B) | (143M) | 1.07B | (2.04B) |
| Investing Cash Flow | (11.19B) | (2.62B) | (10.25B) | (11.49B) | (15.61B) |
| Debt Repayment | (632M) | 878M | 875M | (982M) | (566M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (4.8B) | (3.33B) | (3.1B) | (3.21B) | (3.88B) |
| Dividends Paid | (1.84B) | (1.78B) | (1.76B) | (1.73B) | (1.7B) |
| Other Financing Activities | 5.9B | (5.72B) | 1.05B | 2.79B | 6.32B |
| Financing Cash Flow | (1.38B) | (9.95B) | (2.94B) | (3.13B) | 163M |
| Effect of Forex Changes | (13M) | 1.34B | (630M) | (1.06B) | (697M) |
| Net Change in Cash | 252M | 148M | 444M | (571M) | 1.96B |
| Free Cash Flow | 12.83B | 11.37B | 14.26B | 15.12B | 18.11B |
MetLife, Inc.
NYSE:MET
Intrinsic Alpha fair value
Locked
Current Price
$99.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.